Search Results for: "Clinic Roundup"
-
Clinic Roundup
The open-label, dose-escalation trial was conducted in 52 men with hormone-refractory prostate cancer that had progressed despite prior treatment with taxane-based chemotherapy regimensBioWorld Today | Friday, February 15, 2013 -
Clinic Roundup
The final poster reviews results from the Phase I dose-escalation trial of MVA-BN PROBioWorld Today | Thursday, February 14, 2013 -
Clinic Roundup
Dose escalation will continue as planned to the 1,200-mg dose cohort...Following successful completion of the dose-escalation component of the study, an additional expansion cohort may be added at the highest dose of 1,200 mgBioWorld Today | Tuesday, February 12, 2013 -
Clinic Roundup
Vaximm AG, of Basel, Switzerland, said top-line data from its Phase I/II dose-escalation study of oral cancer vaccine VXM01 met key safety and tolerability endpointsBioWorld Today | Friday, February 8, 2013 -
Clinic Roundup
The safety and dose-escalation trial will test GL-ONC1 as administered intrapleurally as a single-agent therapy...Both are open-label, dose-escalation trials, one in B-cell acute lymphoblastic leukemia and the other in B-cell non-Hodgkin's lymphomas, and both are designed to assess the safety and antitumor activity of the CD19-targeted drugBioWorld Today | Thursday, February 7, 2013 -
Clinic Roundup
The two-part study will feature a dose-escalation portion testing the drugs in combination as a second-line treatment, while the second part will be an open-label, randomized study to determine whether treatment with dalantercept plus axitinib can prolong progression-free survival (PFS) vs...The dose-escalation study will evaluate safety, tolerability and efficacy as determined by RECIST criteria and the company's cancer stem cell biomarkersBioWorld Today | Wednesday, February 6, 2013 -
Clinic Roundup
The dose-escalation study is being conducted under an investigational new drug application at two U.SBioWorld Today | Tuesday, February 5, 2013 -
Clinic Roundup
Thirty-five patents with relapsed or refractory disease after at least two previous regimens with other drugs were included in the dose escalation studyBioWorld Today | Friday, January 25, 2013 -
Clinic Roundup
The open-label trial will enroll about 30 patients for the dose-escalation phase, followed by 30 additional patients in the expansion phaseBioWorld Today | Wednesday, January 9, 2013 -
Clinic Roundup
The 30-patient dose escalation trial evaluated the detailed pharmacokinetics of mibefradil administered four times a day and confirmed its safe dose levels for use in a Phase Ib trialBioWorld Today | Monday, January 7, 2013 -
Clinic Roundup
Alnylam expects to initiate the dose-escalation study early this year, enrolling up to 40 healthy volunteers to evaluate safety and tolerability with a secondary assessment of clinical activity measured by serum TTR levelsBioWorld Today | Friday, January 4, 2013 -
Clinic Roundup
A dose-escalation trial is scheduled to begin in JanuaryBioWorld Today | Wednesday, January 2, 2013 -
Clinic Roundup
NewLink Genetics Corp., of Ames, Iowa, published results of a Phase I dose-escalation study of HyperAcute Prostate Cancer Immunotherapy in the Journal of ImmunotherapyBioWorld Today | Friday, December 14, 2012 -
Clinic Roundup
The multicenter trial will enroll up to 30 patients in the Phase I dose escalation component and up to an additional 30 patients, stratified by B-cell malignancy subtype, once the optimal dose is determinedBioWorld Today | Monday, December 10, 2012 -
Clinic Roundup
Patients in the dose-escalation study will receive intradermal injections of RXI-109, a self-delivering RNAi compound designed to reduce CTGF expression, on three occasions over two weeksBioWorld Today | Thursday, December 6, 2012 -
Clinic Roundup
The dose-escalation study enrolled 60 HIV-uninfected adults and tested doses of the vaccine, which comprises an rVSV vector expressing the HIV-1 gag protein, administered by intramuscular injectionBioWorld Today | Wednesday, December 5, 2012 -
Clinic Roundup
The dose-escalation trial enrolled 24 patients with HIV whose CD4 T-lymphocyte levels were over 200/mm and who were receiving antiretroviral therapyBioWorld Today | Tuesday, December 4, 2012 -
Clinic Roundup
in its dose-escalation Phase Ib study of PRTX-100 in rheumatoid arthritis (RABioWorld Today | Friday, November 30, 2012 -
Pharma: Clinic Roundup
The study is composed of two parts: The first will involve sequential dose escalation for assessing dose response and pharmacokinetics/pharmacodynamics, while the second will serve as a confirmatory study to confirm the efficacy and safety of the drugBioWorld Today | Thursday, November 29, 2012 -
Clinic Roundup
Coronado Biosciences Inc., of Burlington, Mass., said it started a Phase I/II dose-escalation trial of allogeneic natural killer (NK) cells activated by its CNDO-109 in patients in first complete remission from acute myeloid leukemia (AML) and who are deemed high risk for relapseBioWorld Today | Thursday, November 29, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.